1Abe K, Matsuo Y, Kadekawa J,et al. Effect of coenzyme Q10 in patients with mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke - like episodes (MELAS) : Evaluation by noninvasive tissue oximetry[ J]. J Neurol Sci, 1999,162 ( 1 ) :65 - 68.
2Scarlato G, Bresolin N, Moroni I, et al. Multicenter trial with ubidecarenone: Treatment of 44 patients with mitochondrial myopathies [ J ]. Rev Neurol (Paris) , 1991,147 (6 - 7 ) : 542 - 548.
3Chen RS, Huang CC, Chu NS. Coenzyme QIO treatment in mitochondrial encephalomyopathies : Short - term double - blind, crossover study[J]. Eur Neurol,1997,37(4) :212 -218.
4Ogasahara S, Nishikawa Y, Yorifuji S, et al. Treatment of Kearns -Sayre syndrome with eoenzyme Q10[ J]. Neurology, 1986, 36(1) : 45 -53.
5Quinzii C, Naini A, Salviati L, et al. A mutation in para- hydroxybenzoate - polyprenyl transferase (COQ2) causes primary coenzyme Q10 deficiency[ J ]. Am J Hum Genet,2006, 78 (2) : 345 - 349.
6Lo pez LC, Schuelke M, Quinzii CM, et al. Leigh syndrome with nephropathy and CoQ10 deficiency due to decaprenyl diphosphate synthase subunit 2 (PDSS2) mutations [ J ]. Am J Hum Genet, 2006,79 (6) : 1125 - 1t29.
7Mollct J, Giurgea I, Schlemmer D, et al. Prenyldiphosphate syn thase, subunit 1 (PDSS1) and OHbenzoate polyprenyltransferase (COQ2) mutations in ubiquinone deficiency and oxidative phosphorylation disorders[J]. J Clin Invest,2007, 117 (3): 765 - 772.
8Mizuno K, Tanaka M, Nozaki S, et al. Antifatigue effects of coenzyme Q10 during physical fatigue[J]. Nutrition,2008,24(4) : 293 - :299.
9Takeo S. Possible mechanism by which coenzyme Q10 improves reoxygenation Oinduced recovery of cardiac contractile force after hypoxia [J]. J Pharmacol Exp Ther, 1986, 243(3): 1131 - 1138.
10Paiva H, Thelen KM, Van Coster R, et al. High -dose statins and skeletal muscle metabolism in humans: A randomized, controlled trial[ J ]. Clinical Pharmacology & Therapeutics,2005,78 (1) :60 -68.
